Promising FELIX Study Results for Obe-cel Support Buy Rating Amidst Strong Remission and Survival Rates

Analyst Gil Blum from Needham reiterated a Buy rating on Autolus Therapeutics (AUTL – Research Report) and keeping the price target at $10.00.

Gil Blum has given his Buy rating due to a combination of factors related to the promising results of the FELIX study for obe-cel in patients with relapsed/refractory acute lymphoblastic leukemia (ALL). The updated analysis shows that a significant portion of patients remain in remission without the need for further therapy, which is a positive indicator compared to other treatments like Tecartus.
With a median follow-up of 33 months, 38% of responders are still in remission, which is a slight decrease from the 40% reported at 21.5 months but remains impressive. Additionally, the overall survival and event-free survival rates are encouraging, and no new safety concerns have emerged. These factors suggest a favorable reception from ALL physicians and potential for increased commercial adoption of obe-cel, supporting the Buy rating.